Dr. Jun Tian 田军
Chief Physician
Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of kidney, bladder, prostate, testicular, penile, and adrenal tumors. Specializes in bladder-sparing therapy for muscle-invasive bladder cancer, photodynamic therapy, and surgical, particle, and targeted therapies for prostate and kidney cancer.
Dr. Tian is Chief Physician and Department Head of Urology at Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center. Dr. Tian earned a bachelor's degree from West China University of Medical Sciences in 1993 and a doctoral degree in surgery from Peking Union Medical College in 2008, and was a visiting scholar at Harvard Medical School. From 1993 to 2016, Dr. Tian worked in the Urology Department at Cancer Hospital, Chinese Academy of Medical Sciences in Beijing, before transferring to the Shenzhen branch in 2017.
Professional roles
- Vice Chair, Minimally Invasive Technology Professional Committee, National Health Enterprise Management Association
- Vice Chair, Youth Committee on Urological and Male Genital Tumors, China Anti-Cancer Association
- Standing Committee Member, Photodynamic Therapy Committee, Wu Jieping Foundation
- Vice President, Urology Branch, Shenzhen Medical Doctor Association
Name order: in Chinese the family name comes first (Tian Jun). Papers usually list the name as Jun Tian or Tian J.
Selected publications
12 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Photodiagnosis Photodyn Ther, 2026 (senior author): Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: A multicenter, prospective single-arm cohort. PubMed 41698628
- Int J Surg, 2026 (senior author): Real-world prognosis of sporadic bilateral RCC: a propensity score-based comparison of synchronous and metachronous cases. PubMed 41147752
- Eur J Med Res, 2025 (senior author): The impact of surgery and survival prediction in patients with bladder neuroendocrine carcinoma: a novel propensity score-matched population-based cohort study. PubMed 40605073
- Front Immunol, 2024 (senior author): Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis. PubMed 39559360
- Front Oncol, 2023 (senior author): Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis. PubMed 37860180
- Front Immunol, 2023 (senior author): Revolutionizing cancer treatment: nanotechnology-enabled photodynamic therapy and immunotherapy with advanced photosensitizers. PubMed 37860012
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion